Costs, resource allocation, and budget impact

Other publications

Jamieson L, Johnson L, Nichols BE, Delaney-Moretlwe S, Hosseinipour MC, Russell C, Meyer-Rath G. Relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis in South Africa based on the HPTN 083 and HPTN 084 trials: a modelled economic evaluation and threshold analysis. Lancet HIV 2022; 

Bershteyn A, Jamieson L, Kim HY, Platais I, Milali MP, Mudimu E, Ten Brink D, Martin-Hughes R, Kelly SL, Phillips AN, Bansi-Matharu L, Cambiano V, Revill P, Meyer-Rath G, Nichols BE. Transmission reduction, health benefits, and upper-bound costs of interventions to improve retention on antiretroviral therapy: a combined analysis of three mathematical models. Lancet Glob Health. 2022 Sep;10(9):e1298-e1306. doi: 10.1016/S2214-109X(22)00310-2. PMID: 35961353.

Larson B, Shroufi A, Muthoga C et al. Induction-phase treatment costs for cryptococcal meningitis in high HIV-burden African countries: New opportunities with lower costs. Wellcome Open Research 2022, 6:140

Long L, Rosen S, Nichols B, Larson B, Ndlovu N, Meyer-Rath G. Getting resources to those who need them: evidence needed to budget for underserved populations carrying a disproportionate HIV burden in sub-Saharan Africa. J Int AIDS Soc 2021; 24 (Suppl 3): e25707. PMID: 34189873

Murphy JP, Kgowedi S, Naidoo N, Girdwood S, Jamieson L, Soeteman D, Resch S, Meyer-Rath G. Role of data from cost and other economic analyses in healthcare decision-making for HIV, TB and sexual/reproductive health programmes in South Africa. Health Policy Plan 2021; online ahead of print.

Dickerson S, Baranov V, Bor J, Barofsky J. Treatment as insurance: HIV antiretroviral therapy offers financial risk protection in Malawi. Health Policy Plan 2020; 35:676-683.

Phillips AN, Cambiano V, Johnson L, Nakagawa F, Homan R, Meyer-Rath G, et al. Potential impact and cost-effectiveness of condomless-sex-concentrated PrEP in KwaZulu-Natal accounting for drug resistance. J Infect Dis 2019.